The Latest Analyst Ratings for Revance Therapeutics
Portfolio Pulse from Benzinga Insights
Revance Therapeutics (NASDAQ:RVNC) has received various analyst ratings in the last quarter, with the majority being bullish. The average price target from these analysts is $32.46, which is significantly higher than the current price of $9.35. However, this average represents a 17.19% decrease from the previous average price target of $39.20.
November 06, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Revance Therapeutics has received mostly bullish ratings from analysts, with a significant upside indicated by the average price target.
The majority of the analyst ratings for Revance Therapeutics have been bullish, indicating a positive outlook for the stock. The average price target is significantly higher than the current price, suggesting a potential upside. However, the decrease in the average price target from the previous quarter could indicate a less optimistic outlook than before.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100